January 14, 2017
Cascadia Capital, an investment bank serving middle market clients globally, recently announced it acted as the exclusive financial adviser to Seattle-based Impel NeuroPharma, a clinical stage biotechnology company developing first-in-class intranasal drug treatments for central nervous system (CNS) disorders.
The Company has developed a novel drug delivery platform (POD technology) that is able to effectively administer various pharmaceutical compounds deep into the upper nasal cavity, and CNS, at therapeutically meaningful levels. By delivering drugs to this region, the POD nasal device allows entire classes of molecules access to the brain that previously were subject to the anatomical limitations associated with intravenous and oral administration (the blood brain barrier). The POD technology has the potential to improve the brain distribution and bioavailability of many drugs, and radically improve the treatment of various central nervous system disorders (including Alzheimer’s, Parkinson’s, and migraine, together representing a historically underserved patient population).
Cascadia Capital assisted the Company in arranging up to $36 million in funding from three life sciences-focused investment firms: Vivo Capital, VenBio, and 5AM Ventures. The Company received $21 million in an initial tranche, with the remaining $15 million to be received upon the accomplishment of certain development and business milestones.
Impel NeuroPharma represents another successful transaction for Cascadia Capital in the Healthcare & Digital Health space. The Healthcare & Digital Health industry is undergoing revolutionary changes in every major traditional sector.
For more information about this transaction, please contact:
Please complete the form below to access this resource.